Telomir Pharmaceuticals announces pricing of initial public offering
Press Room
Telomir Pharmaceuticals, a pre-clinical-stage pharmaceutical company, on Thursday announced the pricing of its initial public offering of 1,000,000 shares of its common stock at a public offering price of $7.00 per share.
Telomir has granted the underwriters a 45-day option to purchase up to an additional 150,000 shares of common stock at the initial public offering price.
The shares are expected to begin trading on Nasdaq on February 9, 2024 under the ticker symbol “TELO.”
The gross proceeds to Telomir from the initial public offering are expected to be $7 million.
The initial public offering is expected to close on February 13.
